A phase 1/2 dose escalation/expansion study of OR2805 alone or in combination in subjects with advanced solid tumors

Category Primary study
JournalJournal of Clinical Oncology
Year 2022
This article has no abstract
Epistemonikos ID: 8bee4818ac51ce9cccbe59f63387c9c899670118
First added on: Feb 15, 2025